Bunge Other Non-Current Liabilities increased by 8.0% to $1.15B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 46.1%, from $786.00M to $1.15B. Over 3 years (FY 2022 to FY 2025), Other Non-Current Liabilities shows an upward trend with a 7.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may indicate rising long-term operational risks or deferred tax burdens, while a decrease suggests the settlement of these obligations.
This represents miscellaneous long-term obligations that do not fit into standard categories like long-term debt or pens...
Peers in the medical device and pharmaceutical sectors often hold similar balances related to deferred tax liabilities and long-term environmental or legal accruals.
other_non_current_liabilities| Q4 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $849.00M | $824.00M | $842.00M | $805.00M | $670.00M | $847.00M | $786.00M | $761.00M | $1.02B | $1.06B | $1.15B |
| QoQ Change | — | -2.9% | +2.2% | -4.4% | -16.8% | +26.4% | -7.2% | -3.2% | +34.6% | +3.8% | +8.0% |
| YoY Change | — | -2.9% | — | — | — | +2.8% | -6.7% | -5.5% | +52.8% | +25.5% | +46.1% |